Company intelligence / Profile preview

Candesant Biomedical

San Francisco, California, United Statescandesant.com ↗

Ownership: Private
Development stage: Commercial

Overview

Candesant Biomedical has developed the Brella® SweatControl Patch™, an FDA-cleared, non-invasive topical patch for adults with excessive sweating. Clinical studies have shown significant sweat reduction lasting up to two months after a single three-minute in-office application. The technology uses targeted alkali thermolysis to inactivate overactive sweat glands with minimal discomfort and no downtime. Two successful clinical studies demonstrated efficacy and safety.

Therapeutic areas: Dermatology
Modalities: DeviceNon-pharmacological therapy (topical patch)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Brella SweatControl Patch

Commercial

Indications: Primary axillary hyperhidrosis

Beyond the preview

Go deeper on Candesant Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candesant Biomedical.

Explore the full profile